| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 07/16/2013 | CA2620026C Method for production of single- and multi-layer microcapsules |
| 07/16/2013 | CA2569664C Lipid encapsulated interfering rna |
| 07/16/2013 | CA2566793C A novel dosage form |
| 07/16/2013 | CA2558582C Stabilised supersaturated solids of lipophilic drugs |
| 07/16/2013 | CA2551121C Crosslinked hyaluronic acid compositions for tissue augmentation |
| 07/16/2013 | CA2549115C Prebiotic and preservative uses of oil-emulsified probiotic encapsulations |
| 07/16/2013 | CA2543496C Antimicrobial composites, films, labelstocks and labels |
| 07/16/2013 | CA2540159C Extended release venlafaxine formulation |
| 07/16/2013 | CA2483980C Non-invasive delivery of polypeptides through the blood-brain barrier, and in vivo selection of endocytotic ligands |
| 07/16/2013 | CA2483120C Polymeric adhesive transdermal patch comprising rotigotine for treatment of restless leg syndrome |
| 07/16/2013 | CA2478629C Method and apparatus for producing dry particles |
| 07/16/2013 | CA2464656C Spray drying methods and compositions thereof |
| 07/16/2013 | CA2445281C Prevention of myocardial infarction induced ventricular expansion and remodeling |
| 07/16/2013 | CA2289742C Method for generating activated t-cells and antigen-pulsed antigen-presenting cells |
| 07/16/2013 | CA2226624C Methods for treatment of allergic asthma |
| 07/15/2013 | CA2818075A1 Reducible self-assembled micelle drug delivery systems |
| 07/11/2013 | WO2013103966A1 Methods for the treatment of multiple sclerosis and other demyelinating disorders |
| 07/11/2013 | WO2013103919A2 Compositions and methods for treating metabolic disorders |
| 07/11/2013 | WO2013103840A1 Anti-cancer composition and method utilizing 3-bp and liposomal reduced glutathione |
| 07/11/2013 | WO2013103830A1 Methods and kits for extending contact lens use |
| 07/11/2013 | WO2013103801A1 Pharmaceutical spray drying |
| 07/11/2013 | WO2013103771A1 Cellulose ethers with improved thermal gel strength |
| 07/11/2013 | WO2013103537A1 Silicone adhesive compositions |
| 07/11/2013 | WO2013103424A2 Silk-based multifunctional biomedical platform |
| 07/11/2013 | WO2013103389A1 Delayed-release formulation for reducing the frequency of urination and method of use thereof |
| 07/11/2013 | WO2013103357A1 Extended-release formulation for reducing the frequency of urination and method of use thereof |
| 07/11/2013 | WO2013103356A1 Delayed release formulation for reducing the frequency of urination and method of use thereof |
| 07/11/2013 | WO2013103318A1 Solid nicotine-comprising dosage form with reduced organoleptic disturbance |
| 07/11/2013 | WO2013103262A1 Stable pharmaceutical formulation for oral administration comprising levocetirizine or a pharmaceutically acceptable salt thereof, and montelukast or a pharmaceutically acceptable salt thereof |
| 07/11/2013 | WO2013102920A1 Stable lyophilized formulation of bendamustine |
| 07/11/2013 | WO2013102907A1 Ophthalmic composition |
| 07/11/2013 | WO2013102899A1 Methods and compositions for treating diabetes |
| 07/11/2013 | WO2013102665A1 Oromucosal liquid estradiol compositions |
| 07/11/2013 | WO2013102651A1 Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide |
| 07/11/2013 | WO2013102410A1 Oral liquid for treating allergic cough |
| 07/11/2013 | WO2013087808A8 Pharmaceutical composition comprising a pyrazolopyrimidine and cyclodextrin |
| 07/11/2013 | WO2013074048A3 Tablet forms comprising quetiapine fumarate |
| 07/11/2013 | WO2013072762A3 Transdermal propranolol patch for treatment of malignant melanoma |
| 07/11/2013 | WO2013052958A3 Antimicrobial compositions and methods employing same |
| 07/11/2013 | WO2013049749A3 pH DEPENDENT CARRIERS FOR TARGETED RELEASE OF PHARMACEUTICALS ALONG THE GASTROINTESTINAL TRACT, COMPOSITIONS THEREFROM, AND MAKING AND USING SAME |
| 07/11/2013 | WO2013030838A3 Dendrimer-lyotropic liquid crystal (llc) systems |
| 07/11/2013 | WO2013020136A3 Treatment of traumatic brain injury |
| 07/11/2013 | WO2013016332A3 Composition and method for treating migraines |
| 07/11/2013 | WO2012085523A3 Skin sanitizer compositions comprising alcohol based emulsion |
| 07/11/2013 | US20130178524 Prostaglandin-containing product |
| 07/11/2013 | US20130178518 Contact Lenses Containing Carotenoid And Method For Making Same |
| 07/11/2013 | US20130178492 Pharmaceutical compositions comprising hydromorphone and naloxone |
| 07/11/2013 | US20130178467 Highly concentrated stable meloxicam solutions |
| 07/11/2013 | US20130178465 Intranasal dexmedetomidine compositions and methods of use thereof |
| 07/11/2013 | US20130178432 Compositions for controlling heartworm infestation |
| 07/11/2013 | US20130177652 Pharmaceutical oral dosage forms comprising dabigatran etexilate and its pharmaceutically acceptable salts |
| 07/11/2013 | US20130177650 Pellet formulation for the treatment of the intestinal tract |
| 07/11/2013 | US20130177647 Methods for manipulating satiety |
| 07/11/2013 | US20130177646 Solid Nicotine-Comprising Dosage Form with Reduced Organoleptic Disturbance |
| 07/11/2013 | US20130177645 Low dosage forms of risedronate or its salts |
| 07/11/2013 | US20130177638 Method for formulating large diameter synthetic membrane vesicles |
| 07/11/2013 | US20130177637 Method for formulating large diameter synthetic membrane vesicles |
| 07/11/2013 | US20130177636 Method for formulating large diameter synthetic membrane vesicles |
| 07/11/2013 | US20130177635 Method for formulating large diameter synthetic membrane vesicles |
| 07/11/2013 | US20130177634 Method for formulating large diameter synthetic membrane vesicles |
| 07/11/2013 | US20130177633 Method for formulating large diameter synthetic membrane vesicles |
| 07/11/2013 | US20130177631 Method and medicament for inhibiting the expression of a given gene |
| 07/11/2013 | US20130177629 Liposomal compositions |
| 07/11/2013 | US20130177623 Preparation Rich in Growth Factor-Based Fibrous Matrices for Tissue Engeering, Growth Factor Delivery, and Wound Healling |
| 07/11/2013 | US20130177622 Medicament for the Treatment of Pain and Inflammation |
| 07/11/2013 | US20130177619 Vitamin powder composition and method of making |
| 07/11/2013 | US20130177613 Packaging assembly for pharmaceutical composition including pimobendan |
| 07/11/2013 | US20130177611 Silk-based drug delivery system |
| 07/11/2013 | US20130177607 Nanocell Drug Delivery System |
| 07/11/2013 | US20130177606 Transdermal therapeutic system with cholinesterase inhibitor |
| 07/11/2013 | US20130177605 Oral film-form base and preparation |
| 07/11/2013 | US20130177604 Compositions and Methods of Treating Metabolic Disorders |
| 07/11/2013 | US20130177603 Methods for the Preparation of Injectable Depot Compositions |
| 07/11/2013 | US20130177602 Layered pharmaceutical formulations |
| 07/11/2013 | US20130177600 Materials and Methods for Altering an Immune Response to Exogenous and Endogenous Immunogens, Including Syngeneic and Non-Syngeneic Cells, Tissues or Organs |
| 07/11/2013 | US20130177599 Methods and kits for extending contact lens use |
| 07/11/2013 | US20130177598 Discrete size and shape specific pharmaceutical organic nanoparticles |
| 07/11/2013 | US20130177550 Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| 07/11/2013 | US20130177542 Osteoporosis Treatment Means and Method |
| 07/11/2013 | US20130177527 Therapeutic agent preparations for delivery into a lumen of the intestinal tract using a swallowable drug delivery device |
| 07/11/2013 | US20130177522 Non-irritating opthalmic povidone-iodine compositions |
| 07/11/2013 | US20130177506 Bio-Available Chlorogenic Acid Preparations for Supplemental Human Consumption and Use |
| 07/11/2013 | US20130177505 Dermal rejuvenation compositions and methods |
| 07/11/2013 | CA2861141A1 Oromucosal liquid estradiol compositions |
| 07/11/2013 | CA2860669A1 Compositions and methods for treating metabolic disorders |
| 07/11/2013 | CA2856673A1 Delayed-release formulation for reducing the frequency of urination and method of use thereof |
| 07/11/2013 | CA2801385A1 Oral film-form base and preparation |
| 07/10/2013 | EP2612703A2 Particulate materials |
| 07/10/2013 | EP2612681A1 Coating agent for pharmaceutical solid preparation, pharmaceutical film formulation, and coated pharmaceutical solid preparation |
| 07/10/2013 | EP2612674A1 Freeze-dried recombinant human bone morphogenetic protein-2 preparation |
| 07/10/2013 | EP2612672A1 Bioeffective krill oil compositions |
| 07/10/2013 | EP2612671A1 A clinical preparation of scutellarin and the preparation method thereof |
| 07/10/2013 | EP2612665A1 Topical pharmaceutical compositions comprising bexarotene and a corticosteroide |
| 07/10/2013 | EP2612664A1 Stabilized polyphenol solution and method for stabilizing polyphenol solution |
| 07/10/2013 | EP2612663A1 Extended-release formulation for reducing the frequency of urination and method of use thereof |
| 07/10/2013 | EP2612662A1 Delayed-release formulation for reducing the frequency of urination and method of use thereof |
| 07/10/2013 | EP2612659A1 Panaxatriol saponins enteric pellet, capsule comprising same and method for preparing same |
| 07/10/2013 | EP2612658A1 Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide |
| 07/10/2013 | EP2612657A1 Orally disintegrating tablet |
| 07/10/2013 | EP2612656A1 Process for producing drug block-copolymer composite and pharmaceutical product containing same |